The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Vladimirova L.Yu.

Rostov Research Institute of Oncology, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

Mitashok I.S.

Rostov Research Institute of Oncology, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

Kalabanova E.A.

Rostov Research Institute of Oncology, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

Meshcheryakov P.N.

Rostov Research Institute of Oncology, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

Snezhko T.A.

Rostov Research Institute of Oncology, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

Kabanov S.N.

Rostov Research Institute of Oncology, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

Svetitskaya Ya.V.

Rostov Research Institute of Oncology, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

Zhuzhelenko I.A.

Rostov Research Institute of Oncology, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

Oskin S.V.

Rostov Research Institute of Oncology, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

A clinical case of sorafenib use in the treatment of hepatocellular carcinoma

Authors:

Vladimirova L.Yu., Mitashok I.S., Kalabanova E.A., Meshcheryakov P.N., Snezhko T.A., Kabanov S.N., Svetitskaya Ya.V., Zhuzhelenko I.A., Oskin S.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2017;6(5): 70‑73

DOI: 10.17116/onkolog20176570-73

Read: 4849 times

Download PDF (RU)
Contact the author
Table of contents

A CLINICAL CASE OF SORAFENIB USE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA
A CLINICAL CASE OF SORAFENIB USE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA

To cite this article:

Vladimirova LYu, Mitashok IS, Kalabanova EA, et al. . A clinical case of sorafenib use in the treatment of hepatocellular carcinoma. P.A. Herzen Journal of Oncology. 2017;6(5):70‑73. (In Russ.)
https://doi.org/10.17116/onkolog20176570-73

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Clinical significance of gene­tic muta­tions in epithelial tumors of the thymus. P.A. Herzen Journal of Onco­logy. 2025;(2):70-75
Abstract:

Treatment of patients with hepatocellular carcinoma is a topical issue of modern oncology. This disease is included by the World Health Organization in the list of 130 major causes of morbidity and mortality. The paper describes a clinical case of hepatocellular carcinoma in a patient treated with three action methods: the antitumor drug sorafenib at a dose of 400 mg orally twice daily, hepatic transarterial chemoembolization (performed 5 times) and surgical treatment as extended left hemihepatectomy, cholecystectomy with resection of the bile duct confluence and reconstruction of the right hepatic and S 1 ducts on the frame drainage by Pikovsky, lymphadenectomy of the hepatoduodenal ligament. It demonstrates the efficiency of combining the above three methods (the female patient receives the treatment for 24 months; her condition is satisfactory, ECOG grade 0).

Keywords:

hepatocellular carcinoma
sorafenib
hepatic transarterial chemoembolization

Authors:

Vladimirova L.Yu.

Rostov Research Institute of Oncology, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

Mitashok I.S.

Rostov Research Institute of Oncology, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

Kalabanova E.A.

Rostov Research Institute of Oncology, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

Meshcheryakov P.N.

Rostov Research Institute of Oncology, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

Snezhko T.A.

Rostov Research Institute of Oncology, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

Kabanov S.N.

Rostov Research Institute of Oncology, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

Svetitskaya Ya.V.

Rostov Research Institute of Oncology, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

Zhuzhelenko I.A.

Rostov Research Institute of Oncology, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

Oskin S.V.

Rostov Research Institute of Oncology, Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

Close metadata

References:

  1. Khazanov AI. Gepatotsellyulyarnaya kartsinoma. In: Gastroenterologiya i gepatologiya. Мoscow; 2011:759-766. (In Russ.)
  2. Maev IV, Dicheva DT, Zhilyaev EV, Berezutskaya OV, Bitkova EN. Difficulties in diagnosing hepatocellular carcinoma. Consilium medicum. 2010;12(8):63-66. (In Russ.)
  3. Siegel R, Jiemin M, Zhaohui Z, Ahmedin Jemal. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29. https://doi.org/10.3322/caac.21208
  4. Practical recommendations for the treatment of malignant tumors of the Russian Society of Clinical Oncology. Moscow: Versiya; 2016:292-299. (In Russ.)
  5. Shpangenberg KhTs, Timme R. Hepatocellular carcinoma. Meditsinskii sovet. 2011;9-10:112-115. (In Russ.)
  6. Breder VV, Kosyrev VYu, Kudashkin NE, Laktionov K.K. Hepatocellular carcinoma as a social and medical problem in the Russian Federation. Meditsinskii sovet. 2016;(10):3-10. (In Russ.)
  7. Dzhuraev MD, Nematov ON. Short-term results of preoperative chemoembolization of hepatic artery in patients with hepatocellular carcinoma caused by cirrhosis. Sibirskii onkologicheskii zhurnal. 2011;(3):70-73. (In Russ.)
  8. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821-829. https://doi.org/10.1016/j.jhep.2012.06.014
  9. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Dis. 2006;5(10):835-844. https://doi.org/10.1038/nrd2130
  10. Ryadinskaya LA, Shaposhnikov AV, Nepomnyashchaya EM. The comorbid disorders in hepatocellular cancer. Vrach-aspirant. 2013;57(2.1):144-151. (In Russ.)
  11. Kotenko OG, Grinenko AV, Popov AO, Korshak AA, Gusev AV, Fedorov DA, Grigoryan MS. Innovative technologies in the surgical treatment of hepatocellular carcinoma with tumor portal vein thrombosis. Ukrainskii zhurnal khirurgii. 2013;(2):119-127. (In Russ.)
  12. Li Q, Wang J, Sun Y. Efficacy of postoperative transarterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis — a randomized study. World J Surg. 2006;30(11):2004-2011.
  13. Lau WY. Hepatocellulae carcinoma. World Scientific Pub. Co Inc.; 2008.
  14. Park JW, Koh YH, Kim HB, Kim HY, An S, Choi JI, Woo SM, Nam BH. Phase II study of concurrent transarterial chemoembolization and sorafenib for patients with unresectable hepatocellular carcinoma. J Hepatol. 2012;56(6):1336-1342. https://doi.org/10.1016/j.jhep.2012.01.006
  15. Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F. Transarterial chemoembolization plus Sorafenib: A sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: A randomized clinical trial. Oncologist. 2012;17(3):359-366. https://doi.org/10.1634/theoncologist.2011-0313
  16. Daizhong Liu, Aixiang Liu, Junping Peng, Yong Hu, Xielin Feng. Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib. Eur J Med Res. 2015;20:1. https://doi.org/10.1186/s40001-015-0085-9
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.